CA Patent

CA3103411A1 — Use of ibrutinib for treating and preventing chronic graft versus host disease

Assigned to Pharmacyclics LLC · Expires 2015-04-30 · 11y expired

What this patent protects

ABSTRACT Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease. Date Recu…

USPTO Abstract

ABSTRACT Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease. Date Recue/Date Received 2020-1 2-2 1

Drugs covered by this patent

Patent Metadata

Patent number
CA3103411A1
Jurisdiction
CA
Classification
—
Expires
2015-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.